Lucidone B exhibits significant potential in pharmaceutical applications due to its bioactive properties. It has demonstrated anti-inflammatory and neuroprotective effects in preclinical studies, making it a candidate for research in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Additionally, Lucidone B shows antimicrobial activity against certain pathogenic strains, suggesting possible use in developing new antimicrobial agents. Its ability to modulate cellular signaling pathways also supports investigation in cancer therapy, particularly in inhibiting tumor cell proliferation. Ongoing research focuses on optimizing its bioavailability and evaluating its efficacy in in vivo models for future therapeutic development.